This browser is no longer supported at MarketWatch. It’s an Opportunity for Investors. Privacy Notice, and Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Alexion Pharmaceuticals. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals. Alexion Pharmaceuticals currently has a consensus target price of $155.6818, suggesting a potential upside of 2.70%. Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Alexion Pharmaceuticals has a consensus target price of $155.6818, indicating a potential upside of 2.70%. Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Amgen has higher revenue and earnings than Alexion Pharmaceuticals. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Alexion stock has been a laggard in the pharma space, largely moving sideways in recent years, despite posting strong growth (sales grew at an average of 17% each year over the last 5 years). View real-time stock prices and stock quotes for a full financial overview. Therefore, bargain hunters might want to take advantage of this weakness in the pharma … Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Simply put, patients with PNH lack a type of protein that protects their red blood cells from being targeted by their own immune systems. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. 0.4% of Amgen shares are held by insiders. We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership. Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. To see all exchange delays and terms of use please see disclaimer. Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com. 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Please log in to your account or sign up in order to add this asset to your watchlist. Prices shown are actual historical values and are not adjusted for either splits or dividends. Alexion Pharmaceuticals has lower revenue, but higher earnings than Regeneron Pharmaceuticals. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia. ALXN vs. BMRN: Which Stock Is the Better Value Option? Amgen (NASDAQ:AMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? Receive a free world-class investing education from MarketBeat. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. There are currently 16 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. You can opt out at any time. Alexion Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, Alexion Pharmaceuticals Inc. stock falls Tuesday, underperforms market, Alexion Pharmaceuticals Inc. stock falls Monday, underperforms market, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, Alexion Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, Alexion Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, Alexion Pharmaceuticals Inc. stock rises Thursday, outperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, outperforms market, Immunovant (IMVT) Gains on a Potential Buyout by Roivant. Learn more. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 36.76%. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real … (RTTNews) - British drug major AstraZeneca Plc. For the best MarketWatch.com experience, please update to a modern browser. Log in to see them here or sign up to get started. Stock Alert: Alexion Pharma Up 7% . Learn everything you need to know about successful options trading with this three-part video course. Intraday Data provided by FACTSET and subject to terms of use. Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? Given Amgen's stronger consensus rating and higher possible upside, equities analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals. This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets. How Will Biotech ETFs React to These Q4 Earnings Releases? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock split history for Alexion Pharmaceuticals since 1996. 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alexion Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN). Identify stocks that meet your criteria using seven unique stock screeners. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, John Paulson's Top 5 Buys of the 4th Quarter, BioNano Genomics’ Next Double Won’t Come Easily, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates, Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat, Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates, Pick These 4 Low P/CF Stocks for a Value-Based Portfolio, Gilead (GILD) & Galapagos Discontinue Development of IPF Drug. 76.4% of Gilead Sciences shares are owned by institutional investors. Gilead Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. View which stocks are hot on social media with MarketBeat's trending stocks report. Historical and current end-of-day data provided by FACTSET. Our Accessibility Statement Regeneron Pharmaceuticals presently has a consensus price target of $629.24, indicating a potential upside of 33.47%. Want to see which stocks are moving? Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. This is a breakdown of current ratings and price targets for Gilead Sciences and Alexion Pharmaceuticals, as reported by MarketBeat.com. Leerink Partners Believes Alexion Pharmaceuticals (ALXN) Still Has Room to Grow. Seagen has a consensus target price of $188.4615, indicating a potential upside of 25.03%. Please see … Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. This table compares Amgen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Summary. Looking for new stock ideas? ‘No peace’ for markets until 10-year Treasury yield hits 2%, strategist says, Wisconsin Republican Ron Johnson’s remark about feeling safe in Senate during Capitol riot labeled racist, Marco Rubio links his support for unionizing Amazon workers with an accusation of ‘wokeness’ at company, Vaccine-site volunteers frequently rewarded with early shots, What Bond Investors Should Watch This Week: Fed Decision Edition, Nancy Pelosi’s Husband Bought Up This Investment Firm’s Stock. 4.0% of Alexion Pharmaceuticals shares are held by insiders. May. By using this site you agree to the Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. I want to retire in a college town with warm weather and lower taxes — where should I go? This table compares Alexion Pharmaceuticals and Seagen's top-line revenue, earnings per share and valuation. Get Alexion Pharmaceuticals Inc (ALXN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Do Not Sell My Information. Get short term trading ideas from the MarketBeat Idea Engine. Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Alexion is another strong buy, with eight "buy" ratings and one "hold." This is a breakdown of current ratings and target prices for Biogen and Alexion Pharmaceuticals, as reported by MarketBeat.com. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Currency in USD. Latest Share Price and Events Stable Share Price : ALXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Subscriber Agreement & Terms of Use, Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Alexion Pharmaceuticals (NASDAQ:ALXN) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Alexion Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals. Alexion Pharmaceuticals has higher revenue and earnings than Seagen. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. 83.5% of Biogen shares are owned by institutional investors. Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. The end result i… We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Get daily stock ideas top-performing Wall Street analysts. Should you be buying ALXN stock or one of its competitors? Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Alexion Pharmaceuticals topped Wall Street's fourth-quarter expectations Thursday, but ALXN stock tanked on mixed guidance for 2020.. X. This table compares Alexion Pharmaceuticals and Seagen's net margins, return on equity and return on assets. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? This table compares Gilead Sciences and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation. Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Amgen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. This table compares Biogen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. View our full suite of financial calendars and market data tables, all for free. Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. Visit a quote page and your recently viewed tickers will be displayed here. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Learn more. The major determining factor in this rating is whether the stock is trading close to its 52-week-high. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Alexion is collaborating with Zealand Pharma A/S to discover and develop novel peptide therapies for up to four targets in the complement pathway. Fundamental company data provided by Zacks Investment Research. All quotes are in local exchange time. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Alexion Pharmaceuticals has a consensus price target of $155.6818, suggesting a potential upside of 2.70%. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes? Gilead Sciences presently has a consensus price target of $96.0370, suggesting a potential upside of 56.01%. The Alexion Pharmaceuticals stock price gained 0.0924% on the last trading day (Friday, 12th Mar 2021), rising from $151.45 to $151.59.During the day the stock fluctuated 1.28% from a day low at $149.87 to a day high … This is a breakdown of current ratings and recommmendations for Amgen and Alexion Pharmaceuticals, as reported by MarketBeat. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, 87.2% of Seagen shares are held by institutional investors. Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Receive Analysts' Upgrades and Downgrades Daily. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 4.0% of Alexion Pharmaceuticals shares are held by insiders. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets. © American Consumer News, LLC dba MarketBeat® 2010-2021. Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? This treatment, which is provided once every two weeks via intravenous injection, targets a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). (RTTNews) - British drug major AstraZeneca Plc. Something went wrong while loading Watchlist. The stock's $129 share price and $165 average price target give it a 27% upside. 75.2% of Amgen shares are held by institutional investors. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Export data to Excel for your own analysis. Intraday data delayed at least 15 minutes or per exchange requirements.
Die Technik Des Dramas Freytag Zusammenfassung, Ausländerbehörde Frankfurt Aufenthaltstitel, Staatskanzlei Nrw Stellenangebote, La Vie Est Belle Intense Duftbeschreibung, Handballschuhe Kinder Kempa, Dfb Pokal 2021/22, Ariana Thüringen öffnungszeiten, Camioncito Mercedes Benz En Venta,